BNGO — Bionano Genomics, Inc.

Bionano Genomics, Inc. (BNGO) Q4 and Full Year 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $8.0 million, down 3% from $8.2 million in Q4 2024, but within the preannounced range.
• Full Year 2025 Revenue: $28.5 million, down 7% from $30.8 million in 2024. Core revenue, adjusted for clinical services, was down 2%.
• Flow Cell Sales: 7,554 units sold in Q4, a 6% decline year-over-year; 30,171 units sold for the full year, down 0.4%.
• Non-GAAP Gross Margin: Q4 margin at 43%, up from 42% a year ago; full year margin at 47%, a significant improvement from 35% in 2024.
• Operating Expenses: Q4 non-GAAP operating expenses were $9.7 million, down 9% year-over-year; full year expenses were $36.6 million, down 47% from $68.9 million in 2024.
• Cash Position: Ended 2025 with $29.6 million in cash and equivalents, with a runway extending into 2027.

2. Strategic Updates and Business Highlights

• Strategic Shift: Since September 2024, Bionano has focused on profitable growth from high-volume users rather than aggressive expansion of its installed base.
• Key Strategic Pillars:
  1. Support existing OGM users.
  2. Increase utilization of optical genome mapping (OGM).
  3. Build support for reimbursement and guidelines.
  4. Improve profitability through cost management and product quality.
• Publications and Reimbursement: 2025 saw a record 136 new peer-reviewed publications supporting OGM, and significant advancements in reimbursement with a new Category I CPT code for OGM, increasing the reimbursement rate for hematologic malignancies by 47%.
• Customer Focus: Emphasis on routine-use customers, who represent a significant portion of consumables revenue.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $30 million to $33 million, indicating growth of 5% to 16% over 2025.
• Q1 2026 Guidance: Expected revenue of $6.5 million to $6.7 million, flat to 3% growth year-over-year.
• Growth Drivers: Anticipated growth from existing customers and new system installations, with a focus on routine-use customers.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Both Q4 and full-year revenues declined compared to the previous year, raising concerns about overall demand.
• Flow Cell Sales: A slight decrease in flow cell sales, attributed to supply constraints due to manufacturing delays, which may impact future sales.
• Customer Stability: The transition in strategy raised uncertainties regarding customer stability and demand during 2025.

5. Notable Q&A Insights

• New OGM Systems: Management refrained from providing specific guidance on the number of new OGM systems expected to be installed in 2026, suggesting a cautious approach.
• Flow Cell Sales Expectations: Management indicated that consumable sales volume is expected to align with revenue growth, despite recent supply constraints.
• Catalysts for Growth: The increase in reimbursement rates for OGM is seen as a major catalyst for future growth and adoption.

Overall, Bionano Genomics is navigating a transitional phase with a strategic focus on profitability and customer utilization, while facing challenges in revenue growth and supply chain constraints. The outlook for 2026 appears cautiously optimistic, driven by improved reimbursement structures and a targeted customer approach.